The proteomic blood test could be a noninvasive tool used to improve detection of the condition, which currently takes an average of 7.5 years to diagnose.

The firm will use its blood-based tests to explore connections between Alzheimer's disease and neuronal α-synuclein conditions including Parkinson's disease.

The proteomic blood test could be a non-invasive tool used to improve detection of the condition, which currently takes an average of 7.5 years to diagnose.

Sapient will be an Alamar certified service provider for Alamar's NULISAseq Inflammation panel and its NULISAseq CNS Disease panel.

NEW YORK — Owlstone Medical, a UK-based developer of breath-based diagnostics, said on Wednesday that it has closed a $27 million Series E financing round.

The UK-based firm has issued five Class II recalls for its RX-series analyzers since 2018 for issues related to reagent carryover between subsequent tests.

The test detects HIV-1/2 antibodies in finger prick samples and is intended for use by healthcare professionals in any healthcare setting.

The firm said preliminary core Q4 2024 revenues are expected to be flat, exceeding prior expectations, while its China business has stabilized and will recover.

The rapid spinning disk-based immunoassay technology will enhance BioMérieux's offering at the point of care, the firm said.

The report also indicates that while PAMA has cut spending on routine tests, overall lab spending has risen as genetic testing continues to grow.

The recent clearance and a previous clearance together allow the use of Paige's FullFocus digital pathology image viewing software with scanners by Philips, Leica, and Hamamatsu.

The company said it expects Q4 2024 revenues of roughly $34.9 million, up from $31.5 million in Q4 2023 and above the consensus Wall Street estimate of $34.4 million.